HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio maintains a 'Buy' rating on Altimmune (NASDAQ:ALT) but has lowered the price target from $50 to $15.
August 14, 2023 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Altimmune's price target has been lowered from $50 to $15 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for Altimmune by HC Wainwright & Co. indicates a potential decrease in the stock's value. However, the maintenance of the 'Buy' rating suggests that the analyst still sees potential in the company. This could lead to short-term uncertainty and potential downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100